ROBIN HOWARD W 4

What Happened

Robin Howard, President & CEO (and director) of Nektar Therapeutics, sold 423 shares on February 18, 2026 in an open market/private sale for aggregate proceeds of about $30,879. The reported weighted-average sale price was $73.00 per share (trade prices ranged from $72.51 to $74.00). According to the filing, the sale was executed to satisfy required tax withholding on vested restricted stock units (RSUs) and was not a discretionary sale by the reporting person.

Key Details

• Transaction type: Sale (code S); purpose per filing: tax withholding for vested RSUs (footnote F1).
• Date of transaction: 2026-02-18. Prices: $72.51–$74.00; weighted average $73.00 (footnote F2).
• Shares sold: 423; proceeds reported: $30,879.
• Shares owned after transaction: not disclosed in the provided Form 4.
• Filing date: 2026-02-20 — appears to be filed within the normal 2-business-day window.
• Footnotes: F1 (sale to cover tax withholding, not discretionary); F2 (multiple trades; weighted-average price reported; reporting person will provide full trade details on request).

Context

Sales to cover tax withholding on vested awards are routine and do not necessarily indicate a change in the insider’s view of the company. For retail investors, outright purchases usually carry more interpretive weight than required-withholding sales. This filing is informational and factual — it shows an execution to meet tax obligations rather than a voluntary cash-raising trade.